整合素亚单位α V 在癌症中的临床意义：从小细胞肺癌到泛癌症。
The clinical significance of integrin subunit alpha V in cancers: from small cell lung carcinoma to pan-cancer.
机构信息
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
出版信息
BMC Pulm Med. 2022 Aug 4;22(1):300. doi: 10.1186/s12890-022-02095-8.
BACKGROUND
Little is known about the relationship between integrin subunit alpha V (ITGAV) and cancers, including small cell lung cancer (SCLC).
METHODS
Using large sample size from multiple sources, the clinical roles of ITGAV expression in SCLC were explored using differential expression analysis, receiver operating characteristic curves, Kaplan-Meier curves, etc. RESULTS: Decreased mRNA (SMD = - 1.05) and increased protein levels of ITGAV were detected in SCLC (n = 865). Transcription factors-ZEB2, IK2F1, and EGR2-may regulate ITGAV expression in SCLC, as they had ChIP-Seq (chromatin immunoprecipitation followed by sequencing) peaks upstream of the transcription start site of ITGAV. ITGAV expression made it feasible to distinguish SCLC from non-SCLC (AUC = 0.88, sensitivity = 0.78, specificity = 0.84), and represented a risk role in the prognosis of SCLC (p < 0.05). ITGAV may play a role in cancers by influencing several immunity-related signaling pathways and immune cells. Further, the extensive pan-cancer analysis verified the differential expression of ITGAV and its clinical significance in multiple cancers.
CONCLUSION
ITGAV served as a potential marker for prognosis and identification of cancers including SCLC.
背景
关于整合素亚单位 alpha V（ITGAV）与癌症之间的关系，包括小细胞肺癌（SCLC），目前知之甚少。
方法
利用来自多个来源的大量样本，通过差异表达分析、受试者工作特征曲线、Kaplan-Meier 曲线等方法探讨了 ITGAV 表达在 SCLC 中的临床作用。
结果
在 SCLC（n=865）中检测到 ITGAV 的 mRNA（SMD=-1.05）降低和蛋白水平升高。转录因子-ZEB2、IK2F1 和 EGR2-可能通过在 ITGAV 的转录起始位点上游的 ChIP-Seq（染色质免疫沉淀 followed by sequencing）峰来调节 ITGAV 的表达。ITGAV 的表达使得区分 SCLC 和非 SCLC 成为可能（AUC=0.88，敏感性=0.78，特异性=0.84），并且代表了 SCLC 预后的风险作用（p<0.05）。ITGAV 可能通过影响几种免疫相关信号通路和免疫细胞在癌症中发挥作用。此外，广泛的泛癌症分析验证了 ITGAV 的差异表达及其在多种癌症中的临床意义。
结论
ITGAV 可作为包括 SCLC 在内的癌症预后和鉴定的潜在标志物。
Zotero 插件